MoonLake Immunotherapeutics (MLTX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Immunologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-11-16. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 34/100 (MEDIUM), 35.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 14.31% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Evidence and freshness
Record counts and statuses were computed on 2026-11-21. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.
| PDUFA / FDA dates | 0 | No records No upcoming FDA decision date found in the company's SEC filings |
SEC 8-K filing |
| Clinical trials | 4 | Current Updated within the last 14 days |
ClinicalTrials.gov Registry queried: Nov 16, 2026 · ingested Nov 16, 2026 |
| Insider activity | 0 | Unavailable No record on file; source last refreshed Nov 21, 2026 |
SEC EDGAR Form 4 |
| Dilution risk | 1 | Derived Derived score calculated from SEC data, not a raw record |
DilutionWatch score (derived from SEC filings) source date not recorded · ingested Nov 20, 2026 |
| Short interest | 1 | Current Updated within the last 21 days |
FINRA short interest source date not recorded · ingested Nov 20, 2026 |
| Publications | 7 | Current Updated within the last 30 days |
PubMed source date not recorded · ingested Nov 20, 2026 |
How the signal grade is calculated
The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.
What drives this company's 80.5/100 (grade A):
- Clinical trials: signal score 1.00, weight used 68%, 68.5 points
- Dilution risk: signal score 0.34, weight used 22%, 7.5 points
- Short interest: signal score 0.50, weight used 8%, 4.1 points
- Publications: signal score 0.35, weight used 1%, 0.5 points
Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.
Recent News & SEC Filings
- MoonLake Immunotherapeutics (MLTX) Stock Could Be Above Fair Value On Book Value Concerns
- MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
- Is MoonLake Immunotherapeutics (MLTX) Cheap On Earnings Losses And Sonelokimab Milestones?
- MoonLake Immunotherapeutics Stock In Focus After Quarterly Loss Update
- MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View Holds
- MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet Questions
- MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”
- MoonLake Immunotherapeutics Makes Case for Sonelokimab Approval, RBC Says
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- From pixels to prediction: improving imaging through AI in rheumatology. — EULAR Rheumatol Open 2026 Sep PMID 42857279
- Sonelokimab, a novel interleukin 17A-inhibiting and interleukin 17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: A global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA). — J Am Acad Dermatol 2026 Oct 1 PMID 42822776
- Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial. — Nat Med 2025 Dec PMID 41053449
- Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. — Br J Dermatol 2024 Jan 23 PMID 37715694
- Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. — J Eur Acad Dermatol Venereol 2023 Oct PMID 37335885
7 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for MoonLake Immunotherapeutics.
Full MLTX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.